EFTR

NASDAQ

eFFECTOR Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

$0.19-0.07 (-26.76%)

News25/Ratings9

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.

Price$0.19+0.00 (+0.00%)

2025-04-252025-07-01

Latest news

25 items

630dSEC
SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
630dSEC
SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
630dSEC
SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
630dSEC
SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
633dSEC
SEC Form 15-12G filed by eFFECTOR Therapeutics Inc.
15-12G - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
633dSEC
SEC Form S-8 POS filed by eFFECTOR Therapeutics Inc.
S-8 POS - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
633dSEC
SEC Form S-8 POS filed by eFFECTOR Therapeutics Inc.
S-8 POS - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
633dSEC
SEC Form POS AM filed by eFFECTOR Therapeutics Inc.
POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
633dSEC
SEC Form POS AM filed by eFFECTOR Therapeutics Inc.
POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
633dSEC
SEC Form POS AM filed by eFFECTOR Therapeutics Inc.
POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
633dSEC
SEC Form POS AM filed by eFFECTOR Therapeutics Inc.
POS AM - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
644dSEC
SEC Form 25-NSE filed by eFFECTOR Therapeutics Inc.
25-NSE - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
667dNEWS
eFFECTOR Therapeutics Declared in Default on $75M Oxford Finance Loan
On June 25, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) received written notice from Oxford Finance LLC (“Oxford”) that events of default have occurred with respect to that certain Loan and Security Agreement dated as of March 19, 2021, as amended (the “Loan and Security Agreement”), by and between Oxford, as collateral agent, the parties who are lenders thereunder, the Company and eFFECTOR Therapeutics Operations, Inc., the Company’s wholly owned subsidiary (the “Oxford Notice”). The Oxford Notice indicates that events of default have occurred under the Loan and Security Agreement’s Section 8.3 (Material Adverse Change) and Section 8.5 (Insolvency). The Oxford Notice indicates that a
668dSEC
SEC Form 8-K filed by eFFECTOR Therapeutics Inc.
8-K - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
668dSEC
SEC Form 8-K filed by eFFECTOR Therapeutics Inc.
8-K - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
669dNEWS
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.80% to 39,463.48 while the NASDAQ fell 0.42% to 17,614.80. The S&P 500 also rose, gaining, 0.20% to 5,475.44. Leading and Lagging SectorsEnergy shares jumped by 2.6% on Monday. In trading on Monday, information technology shares fell by 1.1%. Top Headline The Federal Reserve Bank of Dallas’ general business activity index for manufacturing in Texas improved to -15.1 in June compared to -19.4 in May. Equities Trading UP Agrify Corporation (NASDAQ:AGFY) shares shot up 107% to $0.5229. Shares of MicroAlgo Inc. (NASD
669dNEWS
Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%
EFFECTOR Therapeutics Inc (NASDAQ:EFTR) shares are trading lower by 75% to $0.28 during Monday’s session after the company announced that it has terminated its employees and will wind down its operations. Also, the company announced it plans to voluntarily request a delisting of its securities on the Nasdaq. This decision follows a special board meeting and the company expects delisting soon. Craig R. Jalbert, who the company says is experienced in managing distressed businesses, has been appointed as the new CEO, President, Treasurer, Secretary and sole board member to oversee the wind-down process. See Also: Gold Prices Set To Climb To $3,000 On Fed Rate Cuts, Geopolitical Tensions,
669dNEWS
EFFECTOR Therapeutics shares are trading lower after the company announced that it has terminated its employees and will wind down its operations. Also, the company announced it plans to voluntarily request a delisting of its securities on the Nasdaq.
669dSEC
SEC Form 8-K filed by eFFECTOR Therapeutics Inc.
8-K - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
669dNEWS
eFFECTOR Therapeutics To Wind Down Operations And Seek Potential Strategic Alternatives, Expects To Delist From Nasdaq
669dPR
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d
679dSEC
eFFECTOR Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
680dINSIDER
SEC Form 4 filed by Director Loewy Caroline M
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
680dINSIDER
SEC Form 4 filed by Director Klencke Barbara
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
680dINSIDER
SEC Form 4 filed by Director Ehrlich Christopher B
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)